Taisha HALTED and reOPEN -25%
Update Neurogene:
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
High-dose NGN-401 has been well-tolerated, and low-dose NGN-401 continues to show a favorable safety profile
Interim safety data presented at the International Rett Syndrome Foundation (IRSF) ASCEND Summit
https://ir.neurogene.com/news-relea...-first-patient-dosed-high-dose-cohort-ngn-401
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.100(0.80%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.44 | $12.73 | $12.13 | $11.07M | 885.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1215 | $12.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.54 | 804 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |